Executive Summary
Founded by Harry Stratford in 1986, Shire Pharmaceuticals Group plc (Shire) is a leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), renal diseases and human genetics. Shire has operations in the world's key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US. Shire is now the third largest pharmaceutical company in the UK.
Company History
Shire was founded in 1986 in the UK. Over the last 12 years, Shire has accomplished eight mergers & acquisition, growing revenues from $7 million in 1997 to over $2.43 billion in 2007. In 2007 it acquired New River Pharmaceuticals Inc, a leading US drug maker, for $2.3bn
Current Events
Business Model
Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.[1]
Products/Services
The Company focuses its drug research and development on Attention Deficit Hyperactivity Disorder (ADHD) through three of its currently leading medications (Adderall/Adderall XR, Daytrana, and the newly developed Vyvanse). However the Company also works on gastrointestinal (GI) treatments, human genetic therapies (HGT) and renal diseases.
Segments/Customers
Production/Operations
Shire has operations in the world's key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.
Distribution/Routes to Market
Market & Competition
Market Share
Main Competitors
Competitive Strengths and Weaknesses
Management
- Matthew Emmens, Chairman and Non-Executive Director;
- Angus Russell, Chief Executive Officer;
- Graham Hetherington, Chief Financial Officer and Executive Vice President of Global Finance;
Financials
Profit & Loss
Balance sheet
Cashflow
Valuation
Comparable Companies
SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
